Medication Associated Vulnerability Surveillance

General-purpose clinician demonstrator — worked example: heat-related deterioration over the next 24–48 hours

Research demonstrator
Synthetic patient. Illustrative weights only. Not a validated clinical prediction model and not for autonomous medication changes.

1. Current surveillance state

Patient vulnerability6/10
Background susceptibility
Heat exposure8/10
Current + forecast stressor
Medication vulnerability10/10
Heat-relevant medicine mechanisms
Physiological activation8/10
N-of-1 deviation + symptoms

Surveillance conclusion

MAVS-Heat stateHIGH
Trend: Rising
Confidence: Moderate

Heat exposure is high and persistent. Medication-associated vulnerability appears physiologically active, with blood pressure below personal baseline, increased resting heart rate and new postural dizziness.

Clinical boundary: this demonstrator identifies mechanisms and surveillance signals. It does not recommend stopping, withholding or substituting medicines autonomously.

Dominant activated pathways

Suggested clinical review

    2. Patient and medicine inputs

    Baseline patient vulnerability

    Older age / reduced physiological reserve
    Mild renal impairment
    Lives alone
    Cognitive impairment
    Severe frailty
    Previous heat illness

    Component scoring is illustrative and transparent for demonstration purposes.

    Medication mechanisms

    Ramipril 10 mg
    haemodynamic vulnerability / thirst response
    Indapamide 2.5 mg
    diuresis / volume depletion / electrolytes
    Oxybutynin 5 mg twice daily
    anticholinergic impairment of sweating
    Atorvastatin 20 mg
    retained in record; no major heat contribution in this example

    The ACE inhibitor + diuretic interaction is modelled separately from the individual medicine contributions.

    Heat exposure

    34
    30
    23
    Poor access to cooling
    Second or later consecutive hot day

    3. Physiological activation

    N-of-1 physiological comparison

    MeasurePersonal baselineCurrentDeviation
    Resting heart rate68 bpm+14 bpm
    Systolic BP132 mmHg−24 mmHg
    Body temperature36.6 °C+0.6 °C
    Weight78.0 kg−0.8 kg

    Symptoms and behaviour

    Postural dizziness
    Thirst / dry mouth
    Reduced fluid intake
    Reduced activity
    Confusion
    Collapse / syncope

    4. Mechanism trace

    Heat exposure
    thermal + fluid stress
    Medication mechanisms
    diuresis, haemodynamic effects, impaired sweating
    Patient susceptibility
    renal reserve, age, social context
    Physiological activation
    N-of-1 BP/HR/temp/weight deviation
    Surveillance signal
    watch → review → high

    5. Counterfactual medication analysis

    Current and counterfactual states

    These are causal probes, not prescribing instructions. They estimate how much the current surveillance state depends on selected medicine mechanisms.

    Interpretation

    The current state is driven by both substantial heat exposure and medicine-sensitive physiological deviation. Removing a single medicine mechanism computationally lowers vulnerability but does not eliminate heat-related risk.

    Stopping rule: MAVS should escalate from mechanism surveillance to clinician action when a plausible medicine-related pathway is accompanied by clinically meaningful deviation from the patient's baseline or concerning symptoms.

    6. Clinician-readable surveillance narrative

    Medication Associated Vulnerability Surveillance (MAVS) — heat worked example. Synthetic data and illustrative scoring. © 2026 Cassis Ltd / Michael Tremblay concept.